The purpose of this phospho-proteomics study was to demonstrate the broad analysis of cellular protein phosphorylation in cells and tissue as a means to monitor changes in cellular states. As a cancer model, human tumor-derived A431 cells known to express the epidermal growth factor receptor (EGFR) were grown as cell cultures or xenograft tumors in mice. The cells and tumor-bearing animals were subjected to treatments including the EGFR-directed protein kinase inhibitor PK166 and/or EGF stimulation. Whole cell/tissue protein extracts were converted to peptides by using trypsin, and phosphorylated peptides were purified by an affinity capture method. Peptides and phosphorylation sites were characterized and quantified by using a combination of tandem mass spectroscopy (MS) and Fourier transform MS instrumentation (FTMS). By analyzing roughly 10 6 cell equivalents, 780 unique phosphopeptides from approx 450 different proteins were characterized. Only a small number of these phosphorylation sites have been described previously in literature. Although a targeted analysis of the EGFR pathway was not a specific aim of this study, 22 proteins known to be associated with EGFR signaling were identified. Fifty phosphopeptides were found changed in abundance as a function of growth factor or drug treatment including novel sites of phosphorylation on the EGFR itself. These findings demonstrate the feasibility of using phospho-proteomics to determine drug and disease mechanisms, and as a measure of drug target modulation in tissue.
Abstract
The purpose of this phospho-proteomics study was to demonstrate the broad analysis of cellular protein phosphorylation in cells and tissue as a means to monitor changes in cellular states. As a cancer model, human tumor-derived A431 cells known to express the epidermal growth factor receptor (EGFR) were grown as cell cultures or xenograft tumors in mice. The cells and tumor-bearing animals were subjected to treatments including the EGFR-directed protein kinase inhibitor PK166 and/or EGF stimulation. Whole cell/tissue protein extracts were converted to peptides by using trypsin, and phosphorylated peptides were purified by an affinity capture method. Peptides and phosphorylation sites were characterized and quantified by using a combination of tandem mass spectroscopy (MS) and Fourier transform MS instrumentation (FTMS). By analyzing roughly 10 6 cell equivalents, 780 unique phosphopeptides from approx 450 different proteins were characterized. Only a small number of these phosphorylation sites have been described previously in literature. Although a targeted analysis of the EGFR pathway was not a specific aim of this study, 22 proteins known to be associated with EGFR signaling were identified. Fifty phosphopeptides were found changed in abundance as a function of growth factor or drug treatment including novel sites of phosphorylation on the EGFR itself. These findings demonstrate the feasibility of using phospho-proteomics to determine drug and disease mechanisms, and as a measure of drug target modulation in tissue.
Introduction
The wide range of cellular processes that are known to involve protein phosphorylation as central elements of their regulation suggest that a clearer picture of these events would be valuable in understanding cellular physiology. Recent reports have highlighted several techniques demonstrating, to various degrees, an ability to broadly catalog many protein phosphorylation sites (1) (2) (3) . We have employed a modified immobilized metal affinity chromatography (IMAC) approach first reported by Ficarro et al. (1) in a series of differential analyses to identify phosphorylation events that occur following treatment of A431 cells with epidermal growth factor (EGF) or the EGF receptor (EGFR)-directed protein kinase inhibitor, PKI166. By analyzing sample aliquots representing roughly 10 6 cell equivalents, 780 unique phosphopeptides from approx 450 different proteins were characterized. In these phosphoproteins, all three phospho-amino acids were observed in their expected physiological ratios-the great majority being phosphoserines. Only a small number of these phosphorylation sites have been described previously in the literature. Whereas a targeted analysis of the EGFR pathway was not a specific aim of this study, 22 proteins from the EGFR pathway were identified as being phosphorylated, including six sites of phosphorylation on the EGFR itself. Three novel sites of phosphorylation were identified on the EGFR, two of which were differentially phosphorylated in response to EGF and PKI166 treatment. Using a custom-built Fourier transform mass spectrometer (FTMS), approx 350 phosphopeptides were quantified in terms of their relative abundance as a function of growth factor and drug treatment. Fifty of these peptides were found to be differentially phosphorylated by a significant amount, including differential phosphorylation on the EGFR as noted above. Overall, the results that we report provide a representative subset of the phosphoproteome that responds to PKI166 treatment and is involved in EGFR signaling and further validates the utility of this approach for identifying phosphorylation sites and their involvement in both physiological and pathophysiological processes.
The general schema for differential phosphoprofiling is depicted in Fig. 1 . Protein is extracted from cell or tissue lysates and digested with trypsin. Acidic residues are derivatized to form d0 or d3 labeled methyl esters. For protein identification the individual samples are subjected to IMAC to isolate phosphopeptides and analyzed with a 4 h liquid chromatography (LC) gradient on a Q-Star Pulsar using a data dependent tandem mass spectrometry (MS/ MS) algorithm. The data are then searched against public databases using Mascot to identify peptide sequences, sites of phosphorylation, and tentative protein IDs. These data are then manually checked for added veracity.
For determining relative abundance between two samples, differentially labeled samples are pooled prior to IMAC isolation of phosphopeptides and subsequent analysis is performed on a custom-built 7T FTMS. Differentially labeled pairs are identified based on their mass difference of a multiple of three and relative abundance is expressed as a ratio. Phosphopeptide identities are then assigned to specific differential ratios based on alignment of the elution times of abundant marker proteins.
The EGF pathway was chosen to demonstrate the utility of this approach to pharmaceutical research. Overexpression of the EGFR was described to be associated with nonsmall cell lung carcinomas and brain, bladder, breast, and ovarian carcinomas (4) (5) (6) (7) (8) . Deregulation (constitutive activation) of EGFR is also associated with tumorigenesis and progression (9) . ErbB2, most closely related to EGF-R, is overexpressed in approx 25% of primary breast and ovarian tumors; ErbB2 overexpression in these two tumor types correlates with earlier relapse and poor prognosis (10, 11) . A number of therapeutic strategies aimed at blocking EGFR activity have been pursued, the most advanced of which include extracellularly directed antibodies that block ligand binding, Cetuximab (Erbitux) and ABX-EGF, and small molecule ATP-competitive antagonists, Iressa (12) , and Tarceva (13) .
PKI166 is a substituted pyrrolo [2,3-d] pyrimidine and is another ATP-competitive EGFR inhibitor, which exhibits dual inhibition of EGFR and erbB-2 (IC 50 = 1 and 11 nM, respectively) (14) (15) (16) . PKI-166 has shown significant and dose-dependent in vivo anti-tumor activity in several EGFR expressing xenograft models in nude mice following oral administration of 10-100 mg/kg/d (17) . Complete and long-lasting inhibition of EGF-stimulated EGFR autophosphorylation in tumors was observed following administration of a single 100 mg/kg oral dose (18) . This study examines the effect of EGF and PKI166 on the phosphoprofile of the epidermoid tumor-derived A431 cell line in culture and in xenograft tumors grown in nude mice.
Results
Four samples were prepared from both cultured cells and dissected tumors, treated and analyzed as indicated in Table 1 . The results from the phosphopeptide identification analyses are summarized in Table 1 . It is important to note that these statistics are based solely on those peptides that were selected (by the MS software) for sequencing and found to have a confirmed sequence from the Mascot search. Roughly equal numbers of phosphorylation sites were identified from in vivo samples as were found the cell culture samples.
The ratio of the different phosphoamino acids (pS to pT to pY) is very similar between all samples and is consistent with expected physiological ratios. In total, 780 unique phosphopeptides were sequenced and identified from 441 different proteins. Quantitation ratios for 354 unique phosphopeptides from 117 different proteins were generated by matching differentially labeled pairs from the FTMS analysis to corresponding MS/MS data from the Q-Star analysis.
Routinely, greater than 95% of the peptides identified after the modified IMAC enrichment procedure are determined to be phosphorylated. Many more differentially labeled pairs are observed in the FTMS analysis than can be matched to Q-Star identifications, suggesting that these numbers still represent just a small percentage of the phosphopeptides.
A diverse array of proteins were determined to be phosphorylated, including: signaling molecules, kinase, phosphatases, transcription factors, proteins involved in differentiation and apoptosis, RNA processing proteins, and metabolic enzymes (Table 2) . Each protein on this list was identified by MS/MS sequencing of at least one phosphopeptide with a sequence that matches a tryptic peptide within the protein. In many cases multiple phosphorylation sites were identified for each protein.
For example, six sites of phosphorylation were identified within the EGFR itself, including three novel phosphoserine sites.
Whereas the actual identification of any specific phosphoprotein is a statistical event dependent upon selection by the MS software algorithm for sequencing, the numbers of proteins identified per class should be roughly proportional to their diversity, abundance, and phosphorylation status. Thus, the representation of phosphoproteins uniquely identified in the cell line samples compared to the tumor samples (Table 2) pared to a monolayer of cultured cells, and provides an example to support the notion that broad phosphoprotein analysis offers the potential of an unbiased view of the physiological status of a cell or tissue.
Because we compared cell states ±EGF or ±PKI166, we cataloged the phosphoproteins identified that have a known connection to the EGFR signaling pathway (Table 2 ). Approximately 22 proteins that are known to be associated with EGFR signaling were determined to be phosphorylated in at least one sample (shown in bold). This includes EGFR itself and several downstream kinases such as Abl, Pak2, PDK1, and RSK. Eight of these proteins were determined to be differentially phosphorylated in response to EGF and/or PKI166 treatment. Peptides that were determined to be significantly differentially phosphorylated in at least one of the cell line comparisons are listed in Table 3 . A number of phosphopeptides are observed to be more abundant in EGF treated (+) vs untreated (-) A431 cells. Specifically, an EGFR peptide containing two novel phosphoserines is eightfold more abundant in EGF treated cells, while 300 nM PKI166 (cell 2) inhibited formation of this phosphopeptide by a factor of 4, suggesting that regulation of S967 and S971 phosphorylation is stimulated by EGF and inhibited by PKI166. Because PKI166 is a relatively selective EGFR inhibitor, the observed inhibition of phosphorylation of these sites is probably a result of inhibition of EGFR pathways leading to activation of serine kinases and/or serine phosphatases, rather than direct effects on those enzymes.
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The largest finite difference measured was that of ribosomal protein S6. With almost a 10-fold increase in EGF treated vs nontreated and over a 400-fold increase in cells treated with EGF alone compared to those treated with EGF and 300 nM PKI166 (Table 3) , phosphorylation of this peptide is clearly affected by the status of EGFR signaling and modulation by PKI166. The three phosphorylation sites identified on this peptide correspond to phosphorylation sites on ribosomal protein S6 known to correlate with activation of protein synthesis (19, 20) .
To highlight one complication of quantifying phosphopeptides, it should be pointed out that a related phosphopeptide from RPS6 was determined to be >10-fold more abundant in PKI166 treated cells than in cells treated with EGF alone (differential ratio of 0.07). Because this peptide contains two of the same phosphoserines as the peptide described above (pS236 and pS240), this data would appear to be contradictory. However, upon careful inspection this data is consistent with the expected pattern of EGF stimulation of RPS6 phosphorylation and inhibition of RPS6 phosphorylation by PKI166. Briefly, the RPS6 phosphopeptide carrying two phosphosites is decreased because of increased phosphorylation of a third serine (pS235). This third phosphorylation also results in a change in the trypsin cleavage site.
ADAM 17 (A disintegrin and metalloproteinase domain 17) also known as TNF-α converting enzyme (TACE) has multiple splice variants. One splice variant lacks residues 656...827, we found S786 to be phosphorylated, thereby identifying the presence of the long splice variant. TACE regulates EGFR ligand availability in vivo (21) . We found phosphorylation of S786 to be inhibited in the presence of EGF. This suggests the possibility of a novel mechanism regulating TACE mediated production of EGFR ligands through a feedback mechanism.
Cdc2-related kinase 7 (Crk7) also called CDC2 related kinase with an arginine/serinerich (RS) domain (CrkRS), is a 1490 amino acid protein that contains RS domains similar to that of RNA splicing factors and co-localizes with a hyperphosphorylated form of RNA Polymerase II in cells and phosphorylates RNA Polymerase II in vitro (22) . Thus Crk7 may be a link between transcription and splicing machinery. In this study, phosphorylation of Crk 7 on S477, was inhibited by a factor of 3.84 by 300 nM PKI166 treatment. S477 is located within a PEST-like sequence suggesting a possible role for this phosphorylation in regulating Crk7 degradation in response to EGF.
CDC2-Like kinase 5 (CDC2L5) or CDC2 Related Kinase 5 (Crk5) is the full-length amino acid sequence of the cholinesterase-related cell division controller (CHED) kinase, a previously published partial coding sequence23. This ubiquitous nuclear protein, shares a PITAVRE and PITAIRE motif with other Cdc2-related proteins. Antisense-CHED treatment impairs growth and/or differentiation of hematopoietic cells (megakaryocytes), indicating that CHED is a positive growth/differentiation regulator (24) . The kinase domain of CDC2L5 is 89% identical to Crk7 and it also contains a Ser-Arg-rich (RS) domain that may play a role in nuclear localization of the protein. Serines 395, 397, and 400 are localized in the middle of the RS-rich sequence in CDC2L5. Increased phosphorylation of these serines, upon stimulation with EGF, may affect the nuclear targeting necessary for execution of CDC2L5's role in mitotic regulation.
Protein tyrosine phosphatase receptor type f polypeptide (PTPRF) or interacting protein (liprin), α-1(PPFIA1), is a member of a receptor PTPase interacting family that binds to type f receptors such as leukocyte common antigen-related protein (LAR). PPFIA1 binds to the LAR membrane-distal D2 protein tyrosine phosphatase domain and appears to localize LAR to focal adhesions. Both LAR and PPFIA1 decorate the ends of focal adhesions most proximal to the cell nucleus and are excluded from the distal ends of focal adhesions, thus localizing to regions of focal adhesions presumably undergoing disassembly. Therefore, LAR and PPFIA1 may regulate the disassembly of focal adhesions and thus help orchestrate cell-matrix interactions. Increased phosphorylation of PPFIA1 in the presence of 300 nM PKI166 is consistent with the large body of literature claiming a role for EGF signaling in down regulating focal adhesions and thereby stimulating tumor invasion (25, 26) .
The two phosphopeptides from the tumor extracts determined to be increased with EGF treatment are from Keratin (Krt1) and desmoplakin (DSP) ( Table 4) . Significantly, the tumor T3:T4 comparison demonstrated higher levels of phosphorylation of many desmosomal and cytoskeletal proteins (DSP, Keratins, and Plakophilins) in tumors from mice treated with Table 4 Differentially Phosphorylated Peptides Identified From A431 Tumor Samples PKI166 for 1 h (T3) as compared to those treated for 24 h (T4). Similarly EMS1 (Cortactin) and catenin D1 (CTNND1) were shown to have higher levels of phosphorylation at the earlier time point. These data suggest that while EGFR itself may be maximally inhibited at 1 h (data not shown), the inhibition of downstream events affecting the cytoskeleton and gap junctions/ desmosomes lags behind. Maximal inhibition of these events may require transcriptional regulation, protein turnover, and/or other processes that would follow a different time course than EGFR autophosphorylation.
Cortactin plays a role in regulating cortical actin assembly, transmembrane receptor organization and membrane dynamics. Aberrant regulation of cortactin levels contributes to tumor cell invasion and metastasis (27) . EGFstimulation increases phosphorylation of cortactin two-fold on Ser/Thr residues. Mek activation is necessary and sufficient for EGFinduced phosphorylation of Cortactin (28) . In this study, we found increased phosphorylation of Cortactin on S368 upon EGF stimulation and reduced phosphorylation following treatment with PKI166 in vitro (Table 4) . These data are consistent with disruption of the EGFR-MEK-Erk pathway leading to cortical actin rearrangements by PKI166. In vivo phosphorylation of S380 was elevated in 1 h PKI166-treated mice compared to 24 h post-PKI166 delivery. The time course of phosphoregulation of this protein mirrors that of the cytoskeletal and desmosomal proteins identified consistent with its involvement in regulating actin assembly and membrane dynamics. P120 Catenin delta 1 (p120ctn) is implicated both in cell transformation by Src and in ligand-induced receptor signaling through the EGF, PDGF, CSF-1 and Erbb2 receptors (29) . The association of catenins to cadherins produces a complex which is linked to the actin filament network, and which seems to be of primary importance for cadherins cell-adhesion properties (30) . Consistent with a role in EGF-induced signaling, three phosphoserines in p120ctn were found to be differentially regulated in the T3ϺT4 comparison.
This study has further highlighted the utility of the IMAC phosphoprofiling method to catalog large numbers of cellular phosphorylation events. Furthermore, with the addition of the d0/d3 methyl ester labeling step, this method can be used to analyze relative abundance of phosphorylations in different cell states. Significantly, this report is the first to demonstrate the utility of this approach to assess in vivo phosphorylation events.
Overall, this approach offers a novel means to analyze protein function and/or drug interactions in an unbiased way. By taking a global snapshot of a large number of phosphorylation events, effects of protein function or drugs can be observed without guessing which pathways you expect might be altered.
Once data from such a global analysis has been achieved then more targeted approaches, such as co-immunoprecipitations, can be done to obtain more detailed information within affected pathways.
Experimental Protocol
In Vitro A431 Samples 1 × 10 7 A431 cells (confluent monolayer in 75 mm dishes: approx 2 × 10 6 cells per 75 mm dish) were starved for 16 h in medium containing 1% fetal bovine serum (FBS), treated for 60 min with EGF (50 ng/mL) in the presence or absence of PKI166 (300 nM, 3000 nM). Cells were preincubated for 30 min with PKI166 prior to treatment with EGF.
In Vivo A431 Tumor Xenografts
The A431 epidermoid cell line (obtained from the American Type Culture Collection [CRL 1555]) was used to establish sc tumors in female BALB/c nu/nu (nude) mice according to a previously described method (18) and tumors were grown to between 400 and 600 mg in mass. Based upon previous pharmacokinetic determinations PKI166-treated mice received 100 mg/kg po whereas control mice received vehicle (four mice per group). Mice were then sacrificed at 0 h, 1 h, and 24 h after cessation of treatment. Five minutes before sacrifice, the mice were administered 0.5 µg EGF/g body weight iv; a group of vehicle-treated control mice received 0.2 mL 0.9% w/v NaCl instead of EGF. The tumors were dissected free of necrotic material and then divided into halves, snap-frozen in liquid nitrogen and stored at -80°C.
Lysis and Protein Extraction
Cells or tumors were lysed and total protein extracted by using 1 mL of TRIzol Reagent (Invitrogen) per 10 7 cells or 5:1 vol:wt in the case of tumors. RNA and DNA were removed by ethanol precipitation and protein was collected by isopropanol precipitation. Protein pellets were washed with 0.3M guanidine-HCl in ethanol prior to protein solubilization and analysis. Tryptic digests of protein samples were derivatized in the presence of either d0 or d3 methanol as a means to differentially mass-label peptides, as indicated in Table 1 . By this approach, labeled peptide mixtures were combined prior to mass spec analysis, and identical peptides differing by 3 daltons (per esterified methyl group) were identified and quantified for relative abundance.
Sample Preparation
Sample preparation followed the procedure of Ficarro et al. (1) . Briefly, the Trizol protein pellets were solubulized in 1% sodium dodecyl sulfate (SDS) and diluted to 0.2% SDS in digest buffer for digestion overnight with trypsin. The digests were taken to dryness and methyl esters were made using d0 or d3 methanol, as listed in Tables 1 and 2 . After esterification the samples were aliquoted and taken to dryness. Aliquoted samples were stored at -80°C for future use.
IMAC Enrichment
IMAC enrichment followed the procedure of Ficarro et al. (1) . Each sample was subjected to IMAC phosphopeptide enrichment. A metal chelating microcapillary column was washed with ethylene diamine tetraaccetic acid (EDTA) and then charged with iron. The column was acidified and the digested sample was loaded to allow the phosphopeptides to remain on the column. Organic washes were used to remove non-phosphorylated peptides and the phosphopeptides were eluted onto a C-18 precolumn with a phosphate wash.
Qualitative MS analysis
The precolumn was attached to a C-18 analytical column with an emitter tip. The whole column is connected to an Agilent 1100 HPLC such that peptides were eluted in to the Sciex Qstar Pulsar mass spectrometer. For a qualitative look at the phosphopeptides present in a sample we used a 4 h HPLC gradient where solvent A was 0.2M acetic acid (HOAc) and solvent B was 0.2M HOAc in 70% acetonitrile (MeCN). The mass spectrometer is set to acquire MS/MS spectra on the top three most abundant ions in a MS scan. Once a mass is subjected to MS/MS it is placed on an exclusion list for 1 min to allow lesser abundant ions to be selected for MS/MS analysis.
Qualitative Data Analysis
All MS/MS spectra were searched against human-nr database using the Mascot search algorithm. The correct methyl ester, d0 or d3, was used as a static modification and differential modifications of phosphorylated Ser, Thr, and Tyr were used as search parameters. All MS/MS identifications were visually inspected and those deemed correct were added to a phosphopeptide list for each sample.
Quantitative MS Analysis
For quantitative analysis another IMAC enrichment was performed, except that two samples were mixed, one d0 and one d3 labeled sample, and then loaded onto the IMAC column for phospho enrichment. All of the peptides were eluted onto a precolumn and eluted into the mass spectrometer. Either the FTMS or the QStar Pulsar was used for this experiment. A custom-built 7T FTMS was used for this study. During gradient elution of the peptides the ions are accumulated in an external quadrupole and then are pulsed into the trap. Ions are detected for approx 100 ms/s scan event. The current FTMS only produces MS information during the 1 h HPLC gradient. The QStar Pulsar was set to acquire one MS and one MS/MS spectra during a 4 h gradient. All quantitative data is analyzed manually and with software developed at MDS Proteomics. 
